Gastroparesis Clinical Trials 2024

What are the top hospitals conducting gastroparesis research?

When it comes to advancing the understanding and treatment of gastroparesis, several top hospitals are at the forefront of groundbreaking clinical trials. Massachusetts General Hospital in Boston has taken a leading role with three active trials dedicated to this condition, adding to their impressive history of 13 all-time gastroparesis trials since their first recorded trial in 2005. Meanwhile, the Cleveland Clinic Foundation in Cleveland is making significant progress as well, currently conducting three active gastroparesis trials and having initiated their inaugural trial on this condition just recently in 2022.

In Baltimore, Johns Hopkins Bayview Medical Center is also actively involved in tackling gastroparesis through research. With three ongoing clinical trials focused on understanding and treating this disorder, they have built upon a solid foundation of ten previously conducted studies since recording their first gastroparesis trial back in 2012. Similarly committed to finding solutions for patients with gastroparesis is the University of Michigan located in Ann Arbor: although featuring two active clinical trials at present, they have successfully completed five previous studies dating back to their earliest recorded trial on this condition conducted in 2013.

Last but certainly not least among these renowned institutions is Mayo Clinic located in Rochester. While contributing two current gastroparesis trials to the field, they demonstrate an equally strong commitment through eight accomplished studies aimed at improving our understanding and management of this complex disorder; Mayo's involvement dates back more than a decade ago when they initiated their first recorded trial on gastroparesis backin2010.

These top hospitals epitomize medical ingenuity and persistence towards unraveling the mysteries surrounding gastroperesis while endeavoringto provide better care and improved quality of life for those affected by it worldwide.

Which are the best cities for gastroparesis clinical trials?

When it comes to gastroparesis clinical trials, several cities have emerged as key locations for cutting-edge research. Houston, Texas, and Boston, Massachusetts each offer six active trials exploring treatments like CIN-102 Dose 1 and Cognitive Behavioral Therapy respectively. Miami, Florida follows closely behind with five ongoing studies investigating interventions such as Nimacimab. Additionally, Baltimore, Maryland and Little Rock, Arkansas each boast four active trials focused on innovative approaches like Transcutaneous Electroacupuncture and Tradipitant. These cities provide individuals living with gastroparesis access to valuable opportunities for participation in groundbreaking clinical research aimed at improving treatment options and quality of life.

Which are the top treatments for gastroparesis being explored in clinical trials?

Exciting developments are underway in clinical trials for gastroparesis, with several cutting-edge treatments taking center stage. One such treatment is the Atmo Motility Gas Capsule System, currently being explored in one active trial. This innovative system made its debut on the research scene in 2023 and shows great promise for addressing gastroparesis. Another notable contender is the endoscopic per-oral pyloromyotomy (POP) procedure, which has also caught researchers' attention with its potential to alleviate symptoms of gastroparesis. First introduced in 2022, POP is being investigated in one active trial dedicated to advancing our understanding of this condition and improving patient outcomes. Last but not least, there's EndoFLIP - a novel approach that has garnered interest within the medical community since its inception in 2015 as it offers new possibilities for managing gastroparesis symptoms. With one ongoing trial exploring its effectiveness, EndoFLIP continues to make strides towards revolutionizing treatment options for patients affected by this debilitating disorder.

What are the most recent clinical trials for gastroparesis?

Promising developments have emerged in the field of gastroparesis, with recent clinical trials offering hope for improved treatment options. Notably, CIN-102 Dose 1 has entered Phase 2 testing and shows potential as a therapeutic approach for gastroparesis. Additionally, Tradipitant is currently undergoing Phase 3 trials, highlighting its viability as a future treatment option. Nimacimab and Rifaximin have both reached Phase 2 stages, demonstrating their efficacy and safety profiles in managing gastroparesis symptoms. Although Study Drug's trial began earlier in 2016 (Phase 2), it still contributes valuable insights into potential interventions for this condition. These exciting clinical trials signify progress towards better care and outcomes for individuals living with gastroparesis.

What gastroparesis clinical trials were recently completed?

Recently, there have been notable advancements in the field of gastroparesis through the completion of several clinical trials. In March 2022, Processa Pharmaceuticals concluded a trial examining PCS12852 as a potential treatment option for this condition. Similarly, Neurogastrx, Inc. conducted a trial investigating NG101 and completed it in August 2020. These significant milestones highlight ongoing efforts to develop effective therapies for individuals suffering from gastroparesis and offer hope for improved management of this challenging disorder